An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.
about
Targeting of erbB3 receptor to overcome resistance in cancer treatmentCombining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.The promise of anti-ErbB3 monoclonals as new cancer therapeuticsEmerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.HER3 as a Therapeutic Target in Cancer.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.HER-3: hub for escape mechanisms.The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.Neuregulin1beta1 antagonizes apoptosis via ErbB4-dependent activation of PI3-kinase/Akt in APP/PS1 transgenic mice.EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.
P2860
Q26864668-6C448ED0-C735-4C48-B191-BB75341678A8Q35409548-8993C837-8134-47E9-B2D7-47615821E995Q36231908-F4ECBB53-44AB-40B5-AC5A-6F72B67205C1Q36670915-FF209D38-8C9B-45C3-8081-6C37F4F52D6CQ37474367-567C652B-022F-4120-8545-415D24BA0313Q37536346-9B51417A-7B82-4896-BD64-9A477AA77A67Q37690272-C6A6E773-BE0D-4833-8152-330DBA245FA2Q38034347-E229043B-3C07-471E-A20E-FC28D6F1D4AFQ38623361-09968758-8A82-4FA3-8E78-6375A5FFF1AFQ38725101-CF86D2B6-898B-49F0-8601-638B423629D5Q38929801-76CC5896-8703-45A1-831E-BEF8E01D99F9Q41583353-648AFB86-C999-4C19-BB5E-5947591AF575Q41667670-FC6C18EB-28AC-426D-8C52-7DE14FFA3B56Q42615742-0BFAC984-8F2F-4D93-B743-9238B651134DQ47150730-7ACB25D6-AF1A-4237-9AFA-20DA49B4D92A
P2860
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@en
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@nl
type
label
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@en
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@nl
prefLabel
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@en
An ErbB-3 antibody, MP-RM-1, i ...... ation of ErbB-3/Akt signaling.
@nl
P2093
P2860
P50
P356
P1433
P1476
An ErbB-3 antibody, MP-RM-1, i ...... vation of ErbB-3/Akt signaling
@en
P2093
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
M D'Egidio
P G Natali
S Iacobelli
P2860
P2888
P304
P356
10.1038/ONC.2011.322
P407
P577
2011-08-08T00:00:00Z